An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

Completed · Phase 4

Conditions studied: Barrett's Esophagus

In brief

The purpose of the study is to compare the treatment of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients

Key facts

Study ID

NCT00352261

Run by

AstraZeneca

People needed

80

Starts

2006-01-01

Expected to finish

2007-04-01

Last updated by the study team

2009-03-26

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented history (within 2 yrs of histologically proven BE;
• Aged 18-70 (inclusive);
• Willing and able to comply with all study procedures

You may not qualify if…

• Signs of clinically significant GI bleeding within 3 days prior to randomization;
• History of gastric or esophageal surgery;
• Clinically significant illness within 2 weeks prior to first dose of study drug or during study

Where it is running

• Research Site — Phoenix, Arizona, United States
• Research Site — Tucson, Arizona, United States
• Research Site — North Chicago, Illinois, United States
• Research Site — Rochester, Minnesota, United States
• Research Site — Kansas City, Missouri, United States
• Research SIte — Springfield, Missouri, United States
• Research Site — Butte, Montana, United States
• Research Site — Cleveland, Ohio, United States
• Research Site — Philadelphia, Pennsylvania, United States
• Research Site — Knoxville, Tennessee, United States
• Research Site — Dallas, Texas, United States
• Research Site — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.